BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SKB571 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SKB571\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06725381-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKB571: Phase 1 readout est. (NCT06725381)
DESCRIPTION:SKB571\, phase 1.\nStudy: A Phase 1 Study of SKB571 in Subjects
  With Advanced Solid Tumors\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06725381
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308106-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SKB571: Phase 2 readout est. (NCT07308106)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07308106
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564466-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SKB571: Phase 2 readout est. (NCT07564466)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Study of SKB571 in Participants Wit
 h Gastrointestinal Tumors\nEstimated primary completion: 31 August 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07564466
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230405-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20280119
DTEND;VALUE=DATE:20280120
SUMMARY:SKB571: Phase 2 readout est. (NCT07230405)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study of SKB571 in Patient
 s With Lung Cancer\nEstimated primary completion: 19 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07230405
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814066-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:SKB571: Phase 2 readout est. (NCT07814066)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Multicenter\, Open-label\, Phase II
  Umbrella Study to Evaluate the Efficacy and Safety of the Investigational
  Product in Participants With Advanced or Metastatic Pancreatic Cancer\nEs
 timated primary completion: 28 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07814066
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668154-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:SKB571: Phase 2 readout est. (NCT07668154)
DESCRIPTION:SKB571\, phase 2.\nStudy: A Phase II Study to Evaluate the Effi
 cacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants\nE
 stimated primary completion: 30 September 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07668154
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SKB571: Phase 2 readout est. (NCT07622186)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Can
 cer (NSCLC)\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876128-2066@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20290412
DTEND;VALUE=DATE:20290413
SUMMARY:SKB571: Phase 1/2 readout est. (NCT07876128)
DESCRIPTION:SKB571\, phase 1/2.\nStudy: A Clinical Trial of MK-2750 in Part
 icipants With Advanced Solid Tumors (MK-2750-002)\nEstimated primary compl
 etion: 12 April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /skb571#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07876128
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
